Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas
Launched by ERASMUS MEDICAL CENTER · Dec 12, 2023
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the short-term effects of two types of radiation therapy—proton therapy and photon therapy—on patients with specific brain tumors called IDH mutated grade 2 and 3 gliomas. The aim is to see if proton therapy, which targets the tumor more precisely and reduces damage to healthy brain tissue, leads to better outcomes compared to traditional photon therapy. This is important because it could help doctors understand which treatment is safer and more effective for these patients.
To be eligible for the trial, participants must be at least 18 years old and have a confirmed diagnosis of grade 2 or 3 IDH mutated glioma. They should have received radiation treatment between January 1, 2018, and June 30, 2022, and have had chemotherapy afterward. Patients who have previously undergone radiation to the brain or who cannot have MRI scans are not eligible. If you join the study, you can expect to share your treatment experiences and help researchers learn more about the best ways to treat this condition. This trial is currently recruiting participants, and your contribution could make a significant difference in understanding glioma treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histopathologically confirmed WHO grade 2 or grade WHO 3 IDHmt glioma
- • Treatment with radiotherapy delivered between 1 of January 2018 and completed before or on the 30th of June 2022
- • Treatment with chemotherapy delivered after radiotherapy (PCV or Temozolomide)
- • Age ≥ 18 years
- Exclusion Criteria:
- • Prior cranial radiotherapy
- • Contra-indication for MRI imaging
- • Chemotherapy delivered before radiotherapy
- • Dose and fractionation other that standard dose (50.4 Gy in 28 fractions for Grade 2 and 59.5 Gy in 33 fractions for Grade 3)
- • Combination photon and proton therapy
- • Patient has previously opted-out of the use of their data for research
About Erasmus Medical Center
Erasmus Medical Center, located in Rotterdam, Netherlands, is a leading academic medical center renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution within the Erasmus University Rotterdam, the center integrates cutting-edge scientific inquiry with comprehensive patient care, focusing on a wide range of medical specialties. With a strong emphasis on multidisciplinary collaboration, Erasmus Medical Center aims to translate research findings into tangible clinical applications, enhancing treatment options and improving patient outcomes. The institution is dedicated to conducting ethical and rigorous clinical trials that contribute to the global body of medical knowledge and foster advancements in personalized medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rotterdam, , Netherlands
Patients applied
Trial Officials
Alejandra Mendez Romero, MD PhD
Principal Investigator
Assitant Professor, Radiation Oncologist
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported